This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
by Zacks Equity Research
INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.
ALKSPositive Net Change INSMPositive Net Change HOWLPositive Net Change
biotechs earnings medical
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
by Ahan Chakraborty
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
PFEPositive Net Change TBPHPositive Net Change CRMDPositive Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
by Zacks Equity Research
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
BIIBPositive Net Change RHHBYPositive Net Change SUPNPositive Net Change
biotechs earnings medical pharmaceuticals
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
by Zacks Equity Research
IONS' Q3 results top estimates as robust Tryngolza and Wainua sales drive revenue growth. The company raises its 2025 outlook for the third time this year.
AZNPositive Net Change NVSPositive Net Change BIIBPositive Net Change IONSPositive Net Change
biotechs earnings medical pharmaceuticals
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
by Zacks Equity Research
AMRN's third-quarter earnings fall short of expectations, but stronger U.S. Vascepa sales push revenues above estimates.
BEAMPositive Net Change AMRNNegative Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechs earnings
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
by Zacks Equity Research
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
BMYPositive Net Change PFEPositive Net Change ALKSPositive Net Change BNTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biotech ETFs Hovering Around a 52-Week: Here's Why
by Sanghamitra Saha
Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?
IBBPositive Net Change SPYPositive Net Change BBCPositive Net Change XBIPositive Net Change SBIOPositive Net Change BBPPositive Net Change
biotechs etfs
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
ALNYPositive Net Change VRTXPositive Net Change ZTSNegative Net Change EXASPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
by Zacks Equity Research
ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth; 2025 guidance raised after strong demand.
ALKSPositive Net Change ANIPPositive Net Change AVDLPositive Net Change HOWLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
by Zacks Equity Research
GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.
GSKPositive Net Change JNJNegative Net Change VIRNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down
by Zacks Equity Research
Repligen posts strong Q3 results with revenue growth and an earnings beat, yet shares dip as tighter EPS guidance tempers investor optimism.
BEAMPositive Net Change RGENPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechs earnings
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
by Sundeep Ganoria
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.
NVSPositive Net Change PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy
by Zacks Equity Research
BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.
SNYPositive Net Change BMRNPositive Net Change ALKSPositive Net Change HOWLPositive Net Change
biotechs earnings gene-therapy medical
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.
ALNYPositive Net Change VRTXPositive Net Change EXASPositive Net Change CRSPPositive Net Change
biotechs
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
NVSPositive Net Change LLYPositive Net Change INCYPositive Net Change ANIPPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
by Ahan Chakraborty
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechnology biotechs hospitals medical pharmaceuticals
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
by Zacks Equity Research
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
NVSPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change RNAPositive Net Change
biotechs earnings medical pharmaceuticals
Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?
by Sundeep Ganoria
ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.
RHHBYPositive Net Change JNJNegative Net Change ABBVPositive Net Change
biotechs earnings-preview medical pharmaceuticals
Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?
by Kanishka Das
HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.
RHHBYPositive Net Change JNJNegative Net Change HALOPositive Net Change
biotechs
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.
ALNYPositive Net Change INCYPositive Net Change ANIPPositive Net Change EXASPositive Net Change
biotechs
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
RDYPositive Net Change MRKPositive Net Change AMGNPositive Net Change ALVOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
by Ahan Chakraborty
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
BMYPositive Net Change MRKPositive Net Change LLYPositive Net Change GILDPositive Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.
BMYPositive Net Change PFEPositive Net Change BNTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
by Sundeep Ganoria
Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.
NVOPositive Net Change LLYPositive Net Change GPCRPositive Net Change
biotechs medical pharmaceuticals